Immune IQ

Executive Summary

Immune IQ is a San Francisco-based diagnostics company founded in 2019, leveraging AI-driven platforms to provide comprehensive immune system profiling. The company aims to translate complex immunological data into personalized health insights for individuals and healthcare providers, addressing a growing need for precision medicine in immunology. By integrating machine learning with multi-omics data, Immune IQ's platform has the potential to enable early detection of immune-related disorders, optimize treatment strategies, and monitor therapeutic responses. While the company is still in early stages with no disclosed funding or commercial products, its focus on a high-growth market and proprietary AI technology positions it as a promising player in the diagnostics space. Key challenges include validation of its platform through clinical studies and securing partnerships for commercialization.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement65% success
• Q4 2026First Clinical Validation Study Results50% success
• TBDStrategic Partnership with a Major Healthcare Provider40% success